Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
11
×
Tags
biotech
11
×
life sciences
11
×
national blog main
clinical trials
san francisco blog main
innovation
boston blog main
deals
drugs
europe blog main
fda
national
national top stories
san francisco top stories
venture capital
brexit
europe
falsified medicines
labeling
mhra
new york blog main
raleigh-durham blog main
raleigh-durham top stories
regulations
startups
uk
akouos
auris health
cancer
intuitive surgical
investing
ipo
johnson & johnson
medical devices
new york top stories
regenerative medicine
roboticsai
san diego blog main
san diego top stories
texas blog main
What
plans
11
×
medicines
end
brexit
cash
charting
choppy
company
course
dynamic
ipo
period
post
regulation
regulatory
reveals
sciences
transition
uk
announced
deal
developing
fda
life
medical
new
san
acquiring
acquisitions
adult
advance
affects
americans
antonio
approved
area
auris
based
bay
billion
Language
unset
Current search:
plans
×
biotech
×
photo
×
" life sciences "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System
@xconomy.com
4 years ago
Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA
@xconomy.com
4 years ago
Liquid Biopsy Firm Lucence Plans Bay Area Buildout With $20M in Tow
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
5 years ago
Hatteras Launches New Fund With $94M for Life Science Investments
@xconomy.com
5 years ago
GenCure Plans Adult Stem Cell Lab at San Antonio “Innovation Center”
@xconomy.com
5 years ago
Johnson & Johnson to Buy Robotics Startup Auris Health for $3.4B
@xconomy.com
5 years ago
Synthorx Files for IPO to Advance Enhanced Cytokine Drugs